Page 66 - TI Journal 18-1
P. 66

60                                      COHEN



          and Lifestyle (AIBL) study of aging. Neurobiol.   58.  Thal, D. R.; Rub, U.; Orantes, M.; Braak, H.
          Aging 31(8):1275-1283; 2010.                 Phases of Ab-deposition in the human brain
      52.  Rowe, C. C.; Ng, S.; Ackermann, U.; Gong, S. J.;   and its relevance for the development of AD.
          Pike, K.; Savage, G.; Cowie, T. F.; Dickinson, K.   Neurology 58(12):1791-1800; 2002.
          L.; Maruff, P.; Darby, D.; Smith, C.; Woodward,   59.  Theuns, J.; Marjaux, E.; Vandenbulcke, M.;
          M.; Merory, J.; Tochon-Danguy, H.; O’Keefe, G.;   Van Laere, K.; Kumar-Singh, S.; Bormans, G.;
          Klunk, W.E.; Mathis, C.A.; Price, J.C.; Masters,   Brouwers, N.; Van den Broeck, M.; Vennekens,
          C.L.; Villemagne, V.L. Imaging beta-amyloid   K.; Corsmit, E.; Cruts, M.; De Strooper, B.; Van
          burden in aging and dementia. Neurology      Broeckhoven, C.; Vandenberghe, R. Alzheimer
          68(20):1718-1725; 2007.                       dementia caused by a novel mutation located
      53.  Scholl, M.; Wall, A.; Thordardottir, S.; Ferreira,   in the APP C-terminal intracytosolic fragment.
          D.; Bogdanovic, N.; Langstrom, B.; Almkvist, O.;   Hum. Mutat. 27(9):888-896; 2006.
          Graff, C.; Nordberg, A. Low PiB PET retention in   60.  Tomiyama, T.; Nagata, T.; Shimada, H.; Teraoka,
          presence of pathologic CSF biomarkers in Arctic   R.; Fukushima, A.; Kanemitsu, H.; Takuma, H.;
          APP mutation carriers. Neurology 79(3):229-  Kuwano, R.; Imagawa, M.; Ataka, S.; Wada, Y.;
          236; 2012.                                   Yoshioka, E.; Nishizaki, T.; Watanabe, Y.; Mori,
      54.  Shimada, H.; Ataka, S.; Tomiyama, T.; Takechi,   H. A new amyloid beta variant favoring oligo-
          H.; Mori, H.; Miki, T. Clinical course of patients   merization in Alzheimer’s-type dementia. Ann.
          with familial early-onset Alzheimer’s disease   Neurol. 63(3):377-387; 2008.
          potentially lacking senile plaques bearing the   61.  Villemagne, V. L.; Burnham, S.; Bourgeat, P.;
          E693Delta mutation in amyloid precursor pro-  Brown, B.; Ellis, K. A.; Salvado, O.; Szoeke, C.;
          tein. Dement. Geriatr. Cogn. Disord. 32(1):45-  Macaulay, S. L.; Martins, R.; Maruff, P.; Ames. D.;
          54; 2011.                                    Rowe, C.C.; Masters, C.L.; Australian Imaging
      55.  Sperling, R. A.; Aisen, P. S.; Beckett, L. A.;   Biomarkers and Lifestyle (AIBL) Research Group.
          Bennett, D. A.; Craft, S.; Fagan, A. M.; Iwatsubo,   Amyloid beta deposition, neurodegeneration,
          T.; Jack, C. R., Jr.; Kaye, J.; Montine, T. J.; Paark,   and cognitive decline in sporadic Alzheimer’s
          D.C.; Reiman, E.M.; Rowe, C.C.; Siemers, E.;   disease: a  prospective  cohort  study. Lancet
          Stern, Y.; Yaffe, K.; Carrillo, M.C.; Thies, B.;   Neurol. 12(4):357-367; 2013.
          Morrison-Bogorad, M.; Wagster, M.V.; Phelps,   62.  Villemagne, V. L.; Ong, K.; Mulligan, R. S.; Holl,
          C.H. Toward defining the preclinical stages of   G.; Pejoska, S.; Jones, G.; O’Keefe, G.; Ackerman,
          Alzheimer’s disease: recommendations from    U.; Tochon-Danguy, H.; Chan, J. G.; Reininger,
          the National Institute on Aging-Alzheimer’s   C.B.; Fels, L.; Putz, B.; Rohde, B.; Masters,
          Association workgroups on diagnostic guidelines   C.L.; Rowe, C.C. Amyloid imaging with (18)
          for Alzheimer’s disease. Alzheimers Dement.   F-florbetaben in Alzheimer disease and other
          7(3):280-292; 2011.                           dementias. J. Nucl. Med. 52(8):1210-1217; 2011.
      56.  Storandt, M.; Mintun, M. A.; Head, D.; Morris,   63.  Villemagne, V. L.; Pike, K. E.; Chetelat, G.; Ellis,
          J. C. Cognitive decline and brain volume loss   K. A.; Mulligan, R. S.; Bourgeat, P.; Ackermann,
          as signatures of cerebral amyloid-beta peptide   U.; Jones, G.; Szoeke, C.; Salvado, O.; Martins,
          deposition identified with Pittsburgh compound   R.; O’Keefe, G.; Mathis, C.A.; Klunk, W.E.; Ames,
          B: cognitive decline associated with Abeta depo-  D.; Masters, C.L.; Rowe, C.C. Longitudinal
          sition. Arch. Neurol. 66(12):1476-1481; 2009.  assessment of Abeta and cognition in aging and
      57.  Suenaga, T.; Hirano, A.; Llena, J. F.; Yen, S. H.;   Alzheimer disease. Ann. Neurol. 69(1):181-192;
          Dickson, D. W. Modified Bielschowsky stain and   2011.
          immunohistochemical studies on striatal plaques   64.  Villemagne, V. L.; Pike, K. E.; Darby, D.; Maruff,
          in Alzheimer’s disease. Acta Neuropathol.    P.; Savage, G.; Ng, S.; Ackermann, U.; Cowie, T. F.;
          80(3):280-286; 1990.                         Currie, J.; Chan, S. G.; Jones, G.; Tochon-Danguy,
   61   62   63   64   65   66   67   68   69   70   71